|
|
|
|
|
|
Sponsored by: |
Inspire Pharmaceuticals |
Information provided by: | Inspire Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00210015 |
The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.
Condition | Intervention | Phase |
Perennial Allergic Rhinitis |
Drug: INS37217 Nasal Spray |
Phase II |
ChemIDplus related topics: | Salicylsalicylic acid Sodium salicylate INS37217 |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Multi-Center, Randomized, Parallel-Group, Double-Blind, Efficacy and Safety Study of INS37217 Nasal Spray Versus Placebo in Subjects With Perennial Allergic Rhinitis |
Estimated Enrollment: | 630 |
Study Start Date: | December 2002 |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 07-105 |
First Received: | September 13, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00210015 |
Health Authority: | United States: Food and Drug Administration |
|
|
|